Novo Nordisk Plans Q1 Launch Of Long-Acting Insulin Tresiba
This article was originally published in The Pink Sheet Daily
Executive Summary
After initial rejection and resubmission, FDA approves ultra-long-acting insulin Tresiba, and also Ryzodeg, which combines Tresiba and the company’s meal-time insulin NovoLog.